City File: Minnow leaps
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MINNOW of the week was Haemocell, which more than doubled to 210p on news that the tiny pharmaceutical company had won US approval for its blood filtration machine. The shares had been low partly because of the losses incurred on development costs. As a latecomer to the market, however, it still represents a relatively risky investment. Keep clear, but watch for the chance to get in on any relapse.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments